Bifogade filer
Vistin Pharma ASA second quarter presentation 2023_final
Kurs
-0,87%
Likviditet
0,82 MNOK
Kalender
| Tid* | ||
| 2024-11-06 | - | X-dag bonusutdelning VISTN 0.5 |
| 2024-11-06 | - | X-dag halvårsutdelning VISTN 0.5 |
| 2024-10-31 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-23 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-05 | - | X-dag bonusutdelning VISTN 0.5 |
| 2024-06-05 | - | X-dag halvårsutdelning VISTN 0.5 |
| 2024-05-23 | - | Årsstämma |
| 2024-04-24 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-16 | - | Bokslutskommuniké 2023 |
| 2024-01-23 | - | X-dag ordinarie utdelning VISTN 0.75 NOK |
| 2024-01-23 | - | X-dag bonusutdelning VISTN 0.75 |
| 2023-10-25 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-23 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-23 | - | X-dag ordinarie utdelning VISTN 0.00 NOK |
| 2023-05-22 | - | Årsstämma |
| 2023-04-27 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-17 | - | Bokslutskommuniké 2022 |
| 2022-10-26 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-19 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-24 | - | X-dag ordinarie utdelning VISTN 0.00 NOK |
| 2022-05-19 | - | Årsstämma |
| 2022-04-27 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-10-28 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-21 | - | X-dag ordinarie utdelning VISTN 0.50 NOK |
| 2021-05-21 | - | X-dag bonusutdelning VISTN 0.5 |
| 2021-05-20 | - | Årsstämma |
| 2021-04-23 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-19 | - | Bokslutskommuniké 2020 |
| 2020-10-30 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-28 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-24 | - | Extra Bolagsstämma 2020 |
| 2020-05-20 | - | X-dag ordinarie utdelning VISTN 1.00 NOK |
| 2020-05-19 | - | Årsstämma |
| 2020-04-23 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-10-25 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-29 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-23 | - | X-dag ordinarie utdelning VISTN 0.00 NOK |
| 2019-05-22 | - | Årsstämma |
| 2019-04-25 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-19 | - | Bokslutskommuniké 2018 |
| 2018-10-25 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-30 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-25 | - | X-dag ordinarie utdelning VISTN 1.00 NOK |
| 2018-05-08 | - | Årsstämma |
| 2018-04-26 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-27 | - | Bokslutskommuniké 2017 |
| 2017-11-03 | - | X-dag bonusutdelning VISTN 7 |
| 2017-11-02 | - | Extra Bolagsstämma 2017 |
| 2017-10-27 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-31 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-26 | - | X-dag ordinarie utdelning VISTN 1.00 NOK |
| 2017-05-24 | - | Årsstämma |
| 2017-04-26 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-28 | - | Bokslutskommuniké 2016 |
| 2016-10-31 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-30 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-25 | - | X-dag ordinarie utdelning VISTN 0.60 NOK |
| 2016-05-24 | - | Årsstämma |
| 2016-04-28 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-23 | - | Bokslutskommuniké 2015 |
| 2015-10-29 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-26 | - | Kvartalsrapport 2015-Q2 |
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Oslo, Norway, 23rd of August 2023
Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the second quarter and first half of 2023.
Revenue in the second quarter ended at MNOK 107 compared to MNOK 69 in Q2 2022. Increased volume from the new production line compared to the same quarter last year has resulted in more volumes available for sale. Revenue for first half of 2023 ended at MNOK 208 compared to MNOK 102 YTD last year, a 103% increase.
Second quarter EBITDA ended at MNOK 19.6 (MNOK 4.7). EBITDA positively affected by increased sales volume, competitive electricity prices and a stronger EUR vs NOK, partly offset by a stronger USD vs NOK. In addition, economies of scale are materializing as the MEP volume ramps up. EBITDA for first half of 2023 ended at MNOK 33.7 compared to negative MNOK 13.5 YTD 2022.
Net profit ended at MNOK 7.1 (Q2’22: MNOK 0.2) for the second quarter of 2023. Net profit negatively affected with MNOK 3 in the quarter by fair value of future FX cash flow hedging contracts (unrealized loss - no cash effect in quarter).
Operational cash flow in the first half of 2023 was MNOK 54 and has resulted in a change from net debt of MNOK 44 at year end 2022 to a positive net cash of MNOK 3 by end of June.
The second quarter conference call, which will be held today, 23rd of August, at 8.30am (CEST), will be available via webcast and audio through the following access points:
Webcast:
https://edge.media-server.com/mmc/p/jokra7jp
Telephone conference (online registration):
https://register.vevent.com/register/BI6600178838a944b187ed120748334f53
The conference call will be held in English
Please find the Q2 report and presentation enclosed. The report will also be made available on www.vistin.com
*****
For further information, please contact:
Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.